JP2006506463A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506463A5
JP2006506463A5 JP2005502127A JP2005502127A JP2006506463A5 JP 2006506463 A5 JP2006506463 A5 JP 2006506463A5 JP 2005502127 A JP2005502127 A JP 2005502127A JP 2005502127 A JP2005502127 A JP 2005502127A JP 2006506463 A5 JP2006506463 A5 JP 2006506463A5
Authority
JP
Japan
Prior art keywords
alkyl
group
pyrrolidin
ethoxy
propoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005502127A
Other languages
English (en)
Japanese (ja)
Other versions
JP4593464B2 (ja
JP2006506463A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2003/004703 external-priority patent/WO2004041829A1/en
Publication of JP2006506463A publication Critical patent/JP2006506463A/ja
Publication of JP2006506463A5 publication Critical patent/JP2006506463A5/ja
Application granted granted Critical
Publication of JP4593464B2 publication Critical patent/JP4593464B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005502127A 2002-11-04 2003-10-29 Srcチロシンキナーゼ阻害剤としてのキナゾリン誘導体 Expired - Fee Related JP4593464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02292736 2002-11-04
EP03290900 2003-04-10
PCT/GB2003/004703 WO2004041829A1 (en) 2002-11-04 2003-10-29 Quinazoline derivatives as src tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010167576A Division JP2010270143A (ja) 2002-11-04 2010-07-26 Srcチロシンキナーゼ阻害剤としてのキナゾリン誘導体

Publications (3)

Publication Number Publication Date
JP2006506463A JP2006506463A (ja) 2006-02-23
JP2006506463A5 true JP2006506463A5 (cg-RX-API-DMAC7.html) 2006-11-02
JP4593464B2 JP4593464B2 (ja) 2010-12-08

Family

ID=32313852

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005502127A Expired - Fee Related JP4593464B2 (ja) 2002-11-04 2003-10-29 Srcチロシンキナーゼ阻害剤としてのキナゾリン誘導体
JP2010167576A Pending JP2010270143A (ja) 2002-11-04 2010-07-26 Srcチロシンキナーゼ阻害剤としてのキナゾリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010167576A Pending JP2010270143A (ja) 2002-11-04 2010-07-26 Srcチロシンキナーゼ阻害剤としてのキナゾリン誘導体

Country Status (27)

Country Link
US (1) US7462623B2 (cg-RX-API-DMAC7.html)
EP (1) EP1562955B1 (cg-RX-API-DMAC7.html)
JP (2) JP4593464B2 (cg-RX-API-DMAC7.html)
KR (1) KR101089462B1 (cg-RX-API-DMAC7.html)
AR (1) AR041884A1 (cg-RX-API-DMAC7.html)
AT (1) ATE387451T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003278383B2 (cg-RX-API-DMAC7.html)
BR (1) BR0315756A (cg-RX-API-DMAC7.html)
CA (1) CA2503371C (cg-RX-API-DMAC7.html)
CO (1) CO5560578A2 (cg-RX-API-DMAC7.html)
CY (1) CY1108061T1 (cg-RX-API-DMAC7.html)
DE (1) DE60319410T2 (cg-RX-API-DMAC7.html)
DK (1) DK1562955T3 (cg-RX-API-DMAC7.html)
EG (1) EG24957A (cg-RX-API-DMAC7.html)
ES (1) ES2300619T3 (cg-RX-API-DMAC7.html)
IL (1) IL168013A (cg-RX-API-DMAC7.html)
IS (1) IS2568B (cg-RX-API-DMAC7.html)
MX (1) MXPA05004858A (cg-RX-API-DMAC7.html)
MY (1) MY137835A (cg-RX-API-DMAC7.html)
NO (1) NO331951B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ539408A (cg-RX-API-DMAC7.html)
PL (1) PL215161B1 (cg-RX-API-DMAC7.html)
PT (1) PT1562955E (cg-RX-API-DMAC7.html)
RU (1) RU2350618C2 (cg-RX-API-DMAC7.html)
SI (1) SI1562955T1 (cg-RX-API-DMAC7.html)
TW (1) TWI320786B (cg-RX-API-DMAC7.html)
WO (1) WO2004041829A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
NZ556673A (en) * 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2020055755A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN119504612B (zh) * 2024-11-18 2026-04-07 中国海洋大学 一种喹唑啉茋类衍生物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EP0888310B1 (en) * 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
ES2241324T3 (es) 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
HK1046688A1 (zh) 1999-09-21 2003-01-24 Astrazeneca Ab 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153805A0 (en) * 2000-08-09 2003-07-31 Astrazeneca Ab Cinnoline compounds
US20030207878A1 (en) 2000-08-09 2003-11-06 Hennequin Lawrent Francois Andre Chemical compounds
WO2002012226A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
AU2001278609B2 (en) * 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
WO2002030924A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
WO2002030926A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
US20040063733A1 (en) 2000-10-25 2004-04-01 Lambert Christine Marie Paul Quinazoline derivatives
ATE409185T1 (de) * 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
ES2272737T3 (es) 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2002365664A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
EP2292615A1 (en) * 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP1528925B1 (en) 2002-07-09 2009-04-22 Astrazeneca AB Quinazoline derivatives for use in the treatment of cancer
AU2003249000B2 (en) 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
DE602004032310D1 (de) 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Similar Documents

Publication Publication Date Title
KR100821446B1 (ko) 퀴나졸린 유도체
US7049438B2 (en) Quinazoline derivatives for treatment of tumours
US7160891B2 (en) Quinazoline derivatives for the treatment of T cell mediated diseases
US7173135B2 (en) Substituted 3-cyanoquinolines as MEK inhibitors
US7501516B2 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
JP2003535859A5 (cg-RX-API-DMAC7.html)
AU2001278609A1 (en) Quinazoline derivatives
JP2004511480A (ja) キナゾリン誘導体
CA2503371A1 (en) Quinazoline derivatives as src tyrosine kinase inhibitors
JP2006508944A5 (cg-RX-API-DMAC7.html)
US7157467B2 (en) Therapeutic use
WO2003047582A1 (en) Quinoline derivatives as antitumour agents
WO2004108704A1 (en) Pyrimidin-4-yl 3-cyanoquinoline derivatives for use in the treatment of tumours
US7223756B2 (en) Quinazoline compounds with therapeutic use
HK1079195B (en) Quinazoline derivatives as src tyrosine kinase inhibitors